Stephen Foley: Lawyers fight it out with directors, and never mind the shareholders
Stephen Foley is a former Associate Business Editor of The Independent, based in New York. He left in August 2012. In a decade at the paper, he covered personal finance, the UK stock market and the pharmaceuticals industry, and had also been the Business section's share tipster. Between arriving with three suitcases in Manhattan in January 2006 and his departure, he witnessed and reported on a great economic boom turning spectacularly to bust. In March 2009, he was named Business and Finance Journalist of the Year at the British Press Awards.
Saturday 28 January 2012
US Outlook: As the late Steve Jobs faced up to his diagnosis of cancer and tried to face down the disease, he reached for the highest of hi-tech measures: he sequenced his entire DNA.
Our genetic make-up holds clues that can help us to understand the risks and the development of our diseases – cancer in particular, it seems – and therefore can help doctors to choose the drugs that have the best shot at working. It could not save the founder of Apple, but it has helped to shrink the tumours and lengthen the lives of many others.
The Apple founder was so optimistic about the technology, he told his biographer that he would be the first person to outrun pancreatic cancer, or among the last to die from it. But Mr Jobs was a visionary, always ahead of his time.
Desperate cancer patients of considerably less means than Mr Jobs are paying out of pocket to have their genes sequenced. Companies such as 23andme –which gets a lot of publicity because its founder is Anne Wojcicki, wife of Google founder Sergey Brin – are trying to popularise genetic testing for people interested in their ancestry as well as their health. The technology is getting closer and closer to the doctor's surgery, and private health insurers in the US are under increasing pressure to fund more uses for gene sequencing.
So you didn't need to be a Jobsian visionary to foresee a takeover battle for the San Diego gene sequencing company Illumina. That battle finally broke out this week, when Roche, the Swiss pharmaceuticals giant, launched a $5.7bn hostile bid for the company.
I wouldn't expect a quick resolution to this one. Illumina hasn't just rejected the offer, it has also installed a poison pill defence so that any stakebuilding by Roche will be offset by the issue of massive amounts of new stock. Outrageous as they may be, poison pills are still legal in the US.
On the other side, class action lawyers are rounding up shareholders for a legal action against the Illumina board, accusing directors of self-servingly rejecting a premium offer just so they can keep their jobs. Yes, this the US: it's directors vs lawyers, and sod what the shareholder wants.
Illumina shareholders have been wobbling on their commitment to the company. For the moment, the bulk of its business is selling machines and associated supplies to universities and research hospitals, since the bulk of sequencing work is still at the research level rather than for personal diagnostics. That will change in time, but until then the company is suffering from the squeeze on budgets in the public sector.
That is why Severin Schwan, Roche's chief executive, has pounced now. Roche and Illumina are ideal partners for the long run. Roche has been a pioneer in personalised medicine, because it has both a drug development and a diagnostic testing business. As the maker of some of the world's most successful cancer drugs, including Avastin and Herceptin, it has more expertise on this subject than any company, while its diagnostics division has the salesforce to push future generations of Illumina products. In other words, it can afford more than the 18 per cent premium it is offering to Illumina's depressed December share price.
Mr Schwan should pay up. That is what a visionary would do.
Presents unwrapped, turkey gobbled... it's time to relax
- 1 Shia LaBeouf claims he was raped during #IAMSORRY art installation performance
- 2 This letter from a reader explains why women can’t play football
- 3 'You should come to my house and eat cheeses with me': 4-year-old sends adorable love letter to girl at school
- 4 Scientists predict green energy revolution after incredible new graphene discoveries
- 5 Michael Buerk wishes he killed Jimmy Savile when he had the chance - by pushing him overboard a cruise ship
Sean Abbott: Messages of support flood in for bowler after death of Phil Hughes
Plebgate: Andrew Mitchell’s reputation in tatters as judge rules he used the word ‘pleb’
Dr Lam Hoe Yeoh: Voyeur doctor jailed for eight years after using network of hidden cameras to film patients, colleagues and friends on the toilet
Kim Jong-un 'in dire need of allies' within his own government as younger sister appointed to senior role
Scientists predict green energy revolution after incredible new graphene discoveries
Ukip says babies born to immigrants in the UK should be classed as migrants – which would include Nigel Farage’s own children
Obama: The only people with the right to object to immigration are Native Americans
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
Ukip mocked after mistaking Westminster Cathedral – for a mosque
Sarah Vine criticises lesbian mother Jack Monroe: 'If she was unsure about her sexuality, she should have taken greater precautions'
iJobs Money & Business
£Attractive Package: Citifocus Ltd: Prestigious asset management house seeks a...
£Negotiable: Citifocus Ltd: This is a varied role focusing on the firm's mutua...
£90000 - £140000 per annum + benefits: h2 Recruit Ltd: Are you a high achievin...
£25000 - £37000 per annum + benefits: h2 Recruit Ltd: Are you seeking to furth...